Modified stem cell therapy for leukemia after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new way to make a treatment more effective and safer for people with acute myeloid leukemia (AML) that has returned after a stem cell transplant. The treatment modifies your own blood stem cells to remove a marker called CD33, then uses an immunotherapy that targets CD33 on cancer cells, potentially reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older) with a confirmed diagnosis of acute myeloid leukemia (AML).
- Your AML must have returned after a stem cell transplant from a family member (like a sibling or parent).
- You cannot have graft-versus-host disease (GvHD) — a condition where the donor cells attack your body.
- Your leukemia cells must have a specific protein called CD33 on them (confirmed by a lab test).
- You need to have adequate organ function, meaning your kidneys, liver, lungs, and heart are working well enough (tests will be done to check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests a specific transplant method using a half-matched donor to treat high-risk acute myeloid leukemia (AML), a type of blood cancer. It aims to reduce complications and improve outcomes for patients who have not responded to other treatments.
This trial tests a combination of three drugs (sonrotoclax, cladribine, and cytarabine) as a rescue treatment for people whose acute myeloid leukemia (AML) has come back or not responded to previous treatment. The goal is to prepare patients for a stem cell transplant, which may offer a chance for long-term remission.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.